Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Comp…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most a…
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging funct…
Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility…